Gevo raises $107 million in its IPO as synbio stays in the spotlight

Earlier this week, isobutanol producer Gevo raised $107 million in its initial public offering (IPO). The synthetic biology company sold approximately 7.1 million shares at $15 apiece, with shares trading as high as $16.50 shortly afterwards. When Gevo first filed its S-1 in August, we were skeptica...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Ginkgo Bioworks to go public via $17.5 billion SPAC deal

News Commentary | May 13, 2021

Backed by Harry Sloan and Jeff Sagansky, this merger with Soaring Eagle Acquisition will give Ginkgo a pre‑money equity valuation of $15 billion, with an additional $2.5 billion for the combined entity – one of the biggest SPAC deals in recent times. This news comes on the heels of Zymergen's IPO ... To read more, click here.

Amyris partners with Ingredion to bring its Reb M sweetener to B2B market

News Commentary | May 13, 2021

With an estimated transaction value of $100 million, Ingredion will get exclusive license to sell and market Amyris' Reb M sweetener technology under this agreement. Additionally, Ingredion will also get a minority stake in Amyris' new production facility in Brazil, to be completed by Q4 2021. ... Not part of subscription

NovoNutrients raises $9 million to scale its CO₂-to-protein production system

News Commentary | August 10, 2021

The funding, led by Happiness Capital, builds on a previous $4.3 million and brings NovoNutrients' total funding to $9.9 million. E2JDJ, Marinya Capital, and previous investors IndieBio and the Grantham Environmental Trust also participated in the round. NovoNutrients aims to use the funds to scale ... Not part of subscription